Loading patent…
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsCarla KROH, Silke HAAG-DIERGARTEN, Ingo Ulrich LANG, Dagmar Maria POLOTZEK, Tanja Margrit ZIMMERING
Estimating the term…
The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more renal diseases and/or hypertension in a non-human mammal/non-human mammal patient, such as a dog or a cat.
A method of prevention and/or treatment of one or more renal diseases and/or hypertension in a non-human mammal comprising administering to the non-human mammal a pharmaceutical composition comprising one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or a pharmaceutically acceptable form thereof.
(canceled)
A pharmaceutical composition comprising one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or a pharmaceutically acceptable form thereof, wherein the pharmaceutical composition is a fixed-dose-combination (FDC) of the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof and telmisartan or a pharmaceutically acceptable from thereof, and the FDC is a solid or a liquid formulation.
Dependencies are inferred from the claim text.